Anti-Hypertensive Drugs - France

France

In France, the Anti-Hypertensive Drugs market is expected to experience a significant increase in revenue.
By 2024, it is projected to reach €0.50bn.
The market is anticipated to grow steadily over the next few years, with an estimated annual growth rate (CAGR 2024-2029) of -0.40%.
This growth trajectory is expected to result in a market volume of €0.49bn by 2029.
When compared to other countries globally, United States is forecasted to generate the highest revenue in the Anti-Hypertensive Drugs market.
In 2024, it is estimated that United States will generate a revenue of €11,400.00m.
France is experiencing a growing demand for innovative anti-hypertensive drugs, driven by an aging population and a focus on preventive healthcare.

Key regions: Japan, India, Italy, Brazil, South Korea

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

Anti-hypertensive drugs are used to treat high blood pressure, which is a common health issue in France. The market for these drugs has been developing in recent years due to various factors.

Customer preferences: Patients in France prefer to use anti-hypertensive drugs as a long-term solution to their high blood pressure. They prefer drugs that have fewer side effects and are easy to take. In addition, they prefer to use drugs that are prescribed by their doctors.

Trends in the market: The market for anti-hypertensive drugs in France has been growing due to an increase in the number of patients with high blood pressure. The market is also being driven by the development of new drugs that are more effective and have fewer side effects. In addition, there has been an increase in the number of generic drugs available in the market, which has led to a decrease in the price of these drugs.

Local special circumstances: There are some local special circumstances that are affecting the market for anti-hypertensive drugs in France. One of these is the high rate of obesity in the country, which is a major risk factor for high blood pressure. Another factor is the aging population, as high blood pressure is more common in older people. Additionally, the French healthcare system provides good coverage for prescription drugs, which has led to increased demand for these drugs.

Underlying macroeconomic factors: The French economy has been growing in recent years, which has led to an increase in healthcare spending. This has helped to drive the growth of the anti-hypertensive drugs market. In addition, the government has implemented policies to promote the use of generic drugs, which has helped to lower the cost of these drugs. The pharmaceutical industry in France is also a major contributor to the economy, which has led to increased investment in research and development of new drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.